Smith, Moore & Co’s Pfizer PFE Stock Holding History

Smith, Moore & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$911K	Sell	32,450 -1,962	-6%	-$52.2K	0.07%	229
2025 Q4	$857K	Sell	34,412 -5,551	-14%	-$140K	0.06%	228
2025 Q3	$1.02M	Sell	39,963 -3,415	-8%	-$84.3K	0.08%	210
2025 Q2	$1.05M	Buy	43,378 +254	+0.6%	+$5.92K	0.09%	199
2025 Q1	$1.09M	Sell	43,124 -2,635	-6%	-$69K	0.1%	188
2024 Q4	$1.21M	Sell	45,759 -16,476	-26%	-$447K	0.11%	168
2024 Q3	$1.8M	Sell	62,235 -1,281	-2%	-$37.4K	0.17%	112
2024 Q2	$1.78M	Buy	63,516 +2,204	+4%	+$60.7K	0.18%	110
2024 Q1	$1.7M	Buy	61,312 +5,271	+9%	+$146K	0.18%	114
2023 Q4	$1.61M	Sell	56,041 -7,423	-12%	-$224K	0.19%	105
2023 Q3	$2.11M	Sell	63,464 -884	-1%	-$31.3K	0.28%	75
2023 Q2	$2.36M	Buy	64,348 +1,722	+3%	+$67K	0.3%	73
2023 Q1	$2.56M	Sell	62,626 -628	-1%	-$27.1K	0.35%	59
2022 Q4	$3.24M	Sell	63,254 -1,210	-2%	-$58K	0.45%	38
2022 Q3	$2.82M	Buy	64,464 +2,688	+4%	+$131K	0.43%	47
2022 Q2	$3.24M	Sell	61,776 -1,066	-2%	-$54.3K	0.5%	39
2022 Q1	$3.25M	Buy	62,842 +2,261	+4%	+$117K	0.44%	47
2021 Q4	$3.58M	Buy	60,581 +312	+0.5%	+$15.5K	0.5%	38
2021 Q3	$2.59M	Sell	60,269 -5	-0%	-$222	0.4%	52
2021 Q2	$2.36M	Buy	60,274 +6,657	+12%	+$259K	0.36%	61
2021 Q1	$1.94M	Buy	53,617 +5,668	+12%	+$201K	0.31%	67
2020 Q4	$1.76M	Sell	47,949 -3,239	-6%	-$119K	0.33%	64
2020 Q3	$1.78M	Buy	51,188 +2,541	+5%	+$89.1K	0.37%	56
2020 Q2	$1.51M	Sell	48,647 -1,811	-4%	-$61.5K	0.33%	65
2020 Q1	$1.56M	Buy	50,458 +2,885	+6%	+$98.3K	0.41%	53
2019 Q4	$1.77M	Sell	47,573 -3,541	-7%	-$126K	0.37%	56
2019 Q3	$1.74M	Buy	51,114 +2,655	+5%	+$96.5K	0.39%	58
2019 Q2	$1.99M	Buy	48,459 +197	+0.4%	+$7.82K	0.45%	46
2019 Q1	$1.95M	Sell	48,262 -3,797	-7%	-$152K	0.46%	46
2018 Q4	$2.16M	Sell	52,059 -9,164	-15%	-$380K	0.59%	37
2018 Q3	$2.56M	Buy	61,223 +2,310	+4%	+$88.9K	0.58%	33
2018 Q2	$2.03M	Buy	58,913 +2,617	+5%	+$89.4K	0.51%	41
2018 Q1	$1.9M	Buy	56,296 +1,934	+4%	+$66.5K	0.51%	41
2017 Q4	$1.87M	Buy	54,362 +4,082	+8%	+$139K	0.5%	44
2017 Q3	$1.7M	Buy	50,280 +5,634	+13%	+$181K	0.48%	45
2017 Q2	$1.42M	Buy	44,646 +4,457	+11%	+$141K	0.48%	45
2017 Q1	$1.3M	Buy	40,189 +2,714	+7%	+$85.6K	0.47%	45
2016 Q4	$1.16M	Buy	37,475 +2,511	+7%	+$76.7K	0.44%	46
2016 Q3	$1.12M	Buy	34,964 +1,138	+3%	+$38.1K	0.45%	45
2016 Q2	$1.13M	Sell	33,826 -26,108	-44%	-$833K	0.47%	45
2016 Q1	$1.69M	Buy	59,934 +8,386	+16%	+$240K	0.73%	31
2015 Q4	$1.58M	Buy	51,548 +30,080	+140%	+$946K	0.79%	27
2015 Q3	$640K	Sell	21,468 -1,143	-5%	-$36.6K	0.36%	47
2015 Q2	$719K	Buy	22,611 +714	+3%	+$23.3K	0.37%	46
2015 Q1	$723K	Buy	21,897 +1,455	+7%	+$46.3K	0.38%	46
2014 Q4	$604K	Buy	20,442 +214	+1%	+$6.14K	0.32%	59
2014 Q3	$568K	Buy	20,228 +3,785	+23%	+$106K	0.32%	57
2014 Q2	$463K	Sell	16,443 -3,404	-17%	-$97K	0.28%	66
2014 Q1	$605K	Buy	19,847 +1,215	+7%	+$36.2K	0.36%	52
2013 Q4	$541K	Buy	+18,632	New	+$542K	0.34%	61

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Smith, Moore & Co's PFE Position: Q1 2026 in Review

Smith, Moore & Co reduced its Pfizer (PFE) stake by 5.7% in Q1 2026, selling an estimated $52.2K and leaving 32,450 shares worth $911K. The position accounts for 0.07% of the portfolio, ranked #229.

Smith, Moore & Co first reported a position in PFE in Q4 2013 and has held it in 50 quarters since. The position peaked at $3.58M in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Smith, Moore & Co held 32,450 shares of Pfizer worth $911K as of Q1 2026.
Smith, Moore & Co sold 1,962 Pfizer shares in Q1 2026, an estimated $52.2K.
Pfizer made up 0.07% of Smith, Moore & Co's portfolio in Q1 2026, its #229 holding.
Smith, Moore & Co first reported a position in Pfizer in Q4 2013 and has held it in 50 quarters since.
Smith, Moore & Co's Pfizer position peaked at $3.58M in Q4 2021.
2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.